Literature DB >> 7805427

Study of the efficacy and safety of ciprofloxacin in the treatment of chronic sinusitis.

J P Fombeur1, S Barrault, G Koubbi, J N Laurier, D Ebbo, F Lecomte, N Sorrel, S Dobler.   

Abstract

Over a 12-month period, 56 patients with acute exacerbations of chronic sinusitis were included in this study. The mean age of the patients was 48.6 +/- 10.1 years. The period between the onset of sinus symptoms and inclusion in the study was 10.1 +/- 12.1 years and the exacerbation had lasted 2.4 +/- 4.4 months. Patients were given 500 mg ciprofloxacin twice daily for 9 days. Bacteriological specimens taken at inclusion were positive in 53.6% of cases, 25 Gram-positive and 16 Gram-negative pathogens being isolated. At the end of the treatment, rhinorrhoea, which was the main criterion for evaluation of the efficacy of treatment, had disappeared in 46/54 (85%) patients who were examined. Of the 30 patients whose sinusitis was confirmed by bacteriological test, the bacteria were eradicated in 90% of cases. At the end of a 4-week follow-up period after the end of treatment, the clinical success rate was 74.5%, the partial success rate 21.2% and the failure rate 4.3%. There were no bacteriological recurrences. Ten adverse events were observed in seven patients and in four (7%) of these treatment had to be withdrawn. This study showed ciprofloxacin to be an effective and well tolerated treatment for exacerbations of chronic sinusitis treated in non-hospital practice.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7805427     DOI: 10.1159/000239313

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  1 in total

1.  In-vitro evaluation of a ciprofloxacin and azithromycin sinus stent for Pseudomonas aeruginosa biofilms.

Authors:  Dong-Jin Lim; Daniel Skinner; John Mclemore; Nick Rivers; Jeffrey Brent Elder; Mark Allen; Connor Koch; John West; Shaoyan Zhang; Harrison M Thompson; Justin P McCormick; Jessica W Grayson; Do-Yeon Cho; Bradford A Woodworth
Journal:  Int Forum Allergy Rhinol       Date:  2019-11-06       Impact factor: 3.858

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.